Clinical trials: Lymph Node Positive
Breast Cancer
Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)
This is a prospective, open-lable Phase II clinical trial (ORCHID study) evaluating the effectiveness and safety of oral vinorelbine or capecitabine combined with trastuzumab as adjuvant treatment for patients with lymph node…
- Trial name
- ORCHID (NCT04296162)
- Testing
- Vinorelbine, Capecitabine, Trastuzumab
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Fudan University
Breast Cancer
Positive Node Traced Before Neoadjuvant Chemotherapy (NAC)
To investigate this regression model by injecting and tracing carbon nanoparticles (CNs) into the fusion node prior to NAC in patients with breast cancer.
- Trial name
- NCT03355261
- Testing
- complete remission (CR) group, partial remission (PR) group, stable disease (SD) group
- Where
- 3 sites in China
- Volunteers
- 110 people
- Sponsor
- Shengjing Hospital
Cervical Cancer
A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy
Recent studies have shown that the chance of survival among women with advanced cervical cancer is increased when they receive concurrent chemotherapy and radiation to the pelvis.
- Trial name
- NCT00590967
- Testing
- IMRT extended field external beam radiation therapy, Brachytherapy, Cisplatin
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Washington University School of Medicine
TNBC, Adjuvant Therapy
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
This study is a prospective, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of postoperative chemotherapy combined with QL1706 in patients with high-risk triple-negative breast cancer.
- Conditions
- TNBC, Adjuvant Therapy, Lymph Node Positive
- Trial name
- NCT07622836
- Testing
- Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy
- Where
- China
- Volunteers
- 59 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer, Axillary Lymph Nodes Dissection
Audit of Targeted Sentinel Node Biopsy (TSNB) in Patients With Limited Nodal Disease Undergoing Primary Surgery
Axillary ultrasound scan (AUS) is routinely employed in the UK for preoperative axillary staging and can diagnose approximately 50 - 80% of node positive patients when combined with percutaneous needle biopsy techniques (either…
- Conditions
- Breast Cancer, Axillary Lymph Nodes Dissection, Axillary Metastases, Sentinel Lymph Node Biopsy (SLNB)
- Trial name
- NodeSMART (NCT07085442)
- Testing
- Targeted Sentinel Node Biopsy (TSNB)
- Where
- 14 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
This is a Phase II clinical trial evaluating the efficacy and safety of a new treatment approach for patients with locally advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes on the opposite side of the…
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
- Trial name
- SACTION 2501 (NCT07309952)
- Testing
- Sintilimab, Paclitaxel, Carboplatin (AUC 5)
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Yang Hong
Prostate Cancer
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
The purpose of this study is to determine the safety and effectiveness of Samarium-153 when given in combination with hormonal and external beam radiation therapy in men with high risk prostate cancer.
- Trial name
- NCT00328614
- Testing
- Samarium-153, Total Androgen Suppression (TAS) with Bicalutamide, Total androgen suppression (TAS) with Goserelin Acetate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Breast Cancer
CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer
The investigators designed a phase III clinical trial involving hormone receptor-positive and HER2-positive stage I breast cancer patients.
- Trial name
- Cinderella (NCT07213206)
- Testing
- CDK 4/6 inhibitor combined therapy (omit chemo), standard of care
- Volunteers
- 1,500 people
- Sponsor
- Fudan University
Breast Cancer
Magseed Pro(R)/ Sentimag(R) Gen3
The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B.
- Trial name
- NCT05142787
- Testing
- Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics
- Where
- 6 sites in Germany, United Kingdom
- Volunteers
- 224 people
- Sponsor
- Endomagnetics Ltd.
Hormone Receptor Positive Malignant Neoplasm of Breast
The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population
The main goal of this study is to characterize whether the results of the Oncotype DX® assay affect the physician's treatment recommendations for the adjuvant treatment of women with ER-positive (ER+), early breast cancer (EBC)…
- Trial name
- NCT02347449
- Testing
- Questionnaires, Oncotype Dx Assay
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer, Adjuvant Therapy
Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer
This study is a prospective, open-label, multicenter, single-arm Phase II clinical trial. Based on the use of CDK4/6 inhibitors in endocrine-sensitive luminal-type (ER+/HER2-) breast cancer, it aims to explore the possibility of…
- Trial name
- ELDER (NCT07826052)
- Testing
- CDK4/6 inhibitor, Endocrine Therapy (Optional)
- Volunteers
- 494 people
- Sponsor
- Fudan University
Breast Cancer, Triple Negative Breast Cancer
Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy
This study evaluates whether SLNB can safely be omitted in breast cancer patients with HER2+ or TN tumors who achieve a radiological complete response on MRI after neoadjuvant systemic therapy
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, Sentinel Lymph Node
- Trial name
- ASICS (NCT04225858)
- Testing
- Omission of sentinel lymph node biopsy
- Volunteers
- 340 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer
The purpose of this study is to compare neo-adjuvant therapy of cytotoxic chemotherapy versus GnRHa with tamoxifen , of response rate(RR) in patients of hormone responsive and HER2 negative, lymph node positive, primary breast…
- Trial name
- NEST (NCT01622361)
- Testing
- Adriamycin+Cyclophosphamide>Docetaxel, GnRHa with Tamoxifen
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Asan Medical Center
Urothelial Carcinoma, Bladder Cancer
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
This is a phase II randomized study of standard of care (SOC) neo-adjuvant cisplatin chemotherapy (NAC) versus NAC plus durvalumab in patients with either clinical or pathologic intra-pelvic node-positive urothelial carcinoma of…
- Trial name
- NCT05137262
- Testing
- Abiraterone acetate, Durvalumab, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma of the Oropharynx, Carcinomas of Unknown Primary Site
Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
Based on the evidence summarized in the introduction, the clinician hypothesize that the detection of the presence and expression of HPV-DNA, certain miRNAs, and a certain mutational profile in the tissues and biological fluids…
- Conditions
- Squamous Cell Carcinoma of the Oropharynx, Carcinomas of Unknown Primary Site, High-risk Human Papillomavirus Infection, Liquid Biopsy
- Trial name
- NCT05918510
- Testing
- Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx
- Where
- Italy
- Volunteers
- 142 people
- Sponsor
- Regina Elena Cancer Institute
Head and Neck Neoplasms
Intraoperative Imaging of a PET Positive Lymph Node(s) Using 18FDG and a Dual-Mode, Hand-Held Intraoperative Imager
This study is a prospective collection of data utilizing the Imaging Beta Probe (IBP) in patients with positron emission tomography (PET) positive disease.
- Trial name
- NCT03561324
- Testing
- Imaging Beta Probe (IBP)
- Where
- United States
- Sponsor
- University of Arkansas
Melanoma
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without…
- Trial name
- MelPORT (NCT04594187)
- Testing
- Immunotherapy, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 168 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study
In this multicenter retrospective cohort study the aim is to determine the safety of omission of axillary lymph node dissection in patients with TNBC and HER2+ tumors with residual macrometastases (in the SLN/TAD/TAS or MARI…
- Trial name
- MACRONAC (NCT07546695)
- Testing
- Data Collection from medical records of from an already existing database "ONCOLOGICAL BREAST SURGERY DATABASE OF THE UNIVERSITY HOSPITAL OF BASEL" which was initiated in 2016.
- Where
- Switzerland
- Volunteers
- 600 people
- Sponsor
- University Hospital, Basel, Switzerland
Breast Cancer, Cognitive/Functional Effects
Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Depression, Malnutrition
- Trial name
- NCT00424203
- Testing
- AC regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 17 sites in France
- Volunteers
- 40 people
- Sponsor
- UNICANCER
Breast Carcinoma
Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer
This research trial studies quality of life, employment, and informal care cost analysis in patients with breast cancer receiving chemotherapy.
- Trial name
- NCT00115505
- Testing
- quality-of-life assessment, Questionnaire Administration
- Where
- 227 sites in United States
- Volunteers
- 307 people
- Sponsor
- Alliance for Clinical Trials in Oncology